Quick Answer
Vanda Pharmaceuticals Inc. reported Total Revenue of $216.10 million for fiscal year 2025.
Vanda Pharmaceuticals Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $216.10M +8.7% |
$198.77M +3.2% |
$192.64M -24.3% |
$254.38M -5.3% |
$268.68M +8.3% |
$248.17M +9.2% |
| Revenue (ASC 606) | $216.10M +8.7% |
$198.77M +3.2% |
$192.64M -24.3% |
$254.38M -5.3% |
$268.68M +8.3% |
$248.17M +9.2% |
| Net Income | -$220.47M -1066.5% |
-$18.90M -853.3% |
$2.51M -60.0% |
$6.28M -81.1% |
$33.15M +42.1% |
$23.34M -79.8% |
| Diluted EPS | -$3.74 -1033.3% |
-$0.33 -925.0% |
$0.04 -63.6% |
$0.11 -81.0% |
$0.58 +38.1% |
$0.42 -80.1% |
| Total Assets | $488.95M -25.5% |
$656.20M +1.2% |
$648.44M +2.2% |
$634.25M +6.8% |
$593.79M +11.3% |
$533.46M +10.3% |
| Cash and Equivalents | $84.85M -17.1% |
$102.32M -24.7% |
$135.82M +0.6% |
$135.03M +159.3% |
$52.07M -14.7% |
$61.03M +35.4% |
| Stockholders Equity | $327.19M -39.2% |
$538.55M -1.2% |
$544.91M +3.4% |
$527.20M +4.4% |
$504.93M +11.4% |
$453.27M +10.3% |
| R&D Expense | $109.27M +46.8% |
$74.43M -3.1% |
$76.82M -10.4% |
$85.77M +13.8% |
$75.36M +35.6% |
$55.58M +14.2% |
| Operating Income | -$151.17M -271.8% |
-$40.66M -191.4% |
-$13.95M -320.4% |
$6.33M -85.0% |
$42.16M +54.8% |
$27.24M +19.4% |
| Shares Outstanding | 59.10M +1.4% |
58.31M +1.3% |
57.53M +1.3% |
56.78M +1.6% |
55.90M +1.9% |
54.87M +2.5% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $56.26M | +18.1% | +7.0% |
| Revenue (ASC 606) | September 30, 2025 | $56.26M | +18.1% | +7.0% |
| Net Income | September 30, 2025 | -$22.59M | -324.2% | +17.0% |
| Diluted EPS | September 30, 2025 | -$0.38 | -322.2% | +17.4% |
| Total Assets | September 30, 2025 | $601.14M | -6.8% | -3.8% |
| Cash and Equivalents | September 30, 2025 | $70.02M | -30.3% | -13.5% |
| Stockholders Equity | September 30, 2025 | $466.00M | -13.9% | -4.2% |
| R&D Expense | September 30, 2025 | $22.56M | +34.5% | +2.6% |
| Operating Income | September 30, 2025 | -$31.28M | -184.4% | +18.7% |
| Shares Outstanding | September 30, 2025 | 59.10M | +1.4% | +0.0% |
- Vanda Pharmaceuticals Inc. reported Total Revenue of $216.10 million for fiscal year 2025.
- Vanda Pharmaceuticals Inc. showed an increase of +8.7% in Total Revenue compared to the prior fiscal year.
- Vanda Pharmaceuticals Inc. reported Revenue (ASC 606) of $216.10 million for fiscal year 2025.
- Vanda Pharmaceuticals Inc. showed an increase of +8.7% in Revenue (ASC 606) compared to the prior fiscal year.
- Vanda Pharmaceuticals Inc. reported Net Income of -$220.47 million for fiscal year 2025.
- Vanda Pharmaceuticals Inc. showed a decrease of -1066.5% in Net Income compared to the prior fiscal year.
- Vanda Pharmaceuticals Inc. reported Diluted EPS of $3.74 per share (loss) for fiscal year 2025.
- Vanda Pharmaceuticals Inc. showed a decrease of -1033.3% in Diluted EPS compared to the prior fiscal year.
- Vanda Pharmaceuticals Inc. reported Total Assets of $488.95 million for fiscal year 2025.
- Vanda Pharmaceuticals Inc. showed a decrease of -25.5% in Total Assets compared to the prior fiscal year.
- Vanda Pharmaceuticals Inc. reported Cash and Equivalents of $84.85 million for fiscal year 2025.
- Vanda Pharmaceuticals Inc. showed a decrease of -17.1% in Cash and Equivalents compared to the prior fiscal year.
- Vanda Pharmaceuticals Inc. reported Stockholders Equity of $327.19 million for fiscal year 2025.
- Vanda Pharmaceuticals Inc. showed a decrease of -39.2% in Stockholders Equity compared to the prior fiscal year.
- Vanda Pharmaceuticals Inc. reported R&D Expense of $109.27 million for fiscal year 2025.
- Vanda Pharmaceuticals Inc. showed an increase of +46.8% in R&D Expense compared to the prior fiscal year.
- Vanda Pharmaceuticals Inc. reported Operating Income of -$151.17 million for fiscal year 2025.
- Vanda Pharmaceuticals Inc. showed a decrease of -271.8% in Operating Income compared to the prior fiscal year.
- Vanda Pharmaceuticals Inc. reported Shares Outstanding of 59.10 million shares for fiscal year 2025.
- Vanda Pharmaceuticals Inc. showed an increase of +1.4% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: